Search results
Pakistan probes distributors of Roche cancer drug after patients go blind
Reuters via AOL· 8 months agoLAHORE, Pakistan (Reuters) -Pakistan said on Monday it was investigating two local distributors of...
Top 15 Best-Selling Cancer Drugs
Insider Monkey via Yahoo Finance· 4 months agoIn this article, we will be discussing the top 15 best-selling cancer drugs. If you are not interested in reading about the global cancer treatment...
Here's What is Driving Amgen (AMGN) Stock's Outperformance
Zacks via Yahoo Finance· 1 year agoAmgen AMGN is one of the biggest biotech companies in the world, with a strong presence in the...
What This News Means for Merck
Motley Fool· 2 years agoIn combination with Roche's (OTC: RHHBY) bevacizumab (Avastin), Merck's (NYSE: MRK) oncology medicine -- co-owned with AstraZeneca (NASDAQ: AZN) and...
‘Fit and healthy’ man told he had ‘stomach bug’ diagnosed with stage four bowel cancer
The Independent UK via AOL· 1 year agoA “fit and healthy” man told by his GP he had a “stomach bug” was devastated when it turned out to...
Neovascular Age-Related Macular Degeneration (AMD): What to Know
Verywell Health via Yahoo News· 3 months agoUnderstanding Blood Vessel Formation in Wet AMD Medically reviewed by Christine L. Larsen, MD...
15 Best Hospitals for Cancer Treatment in the US
Insider Monkey via Yahoo Finance· 3 months agoIn this article, we will be taking a look at the 15 best hospitals for cancer treatment in the US. If you are not interested in reading about the global...
Amgen (AMGN) Q2 Earnings Beat Estimates, 2023 View Raised
Zacks via Yahoo Finance· 10 months agoAmgen AMGN reported second-quarter 2023 earnings of $5.00 per share, which beat the Zacks Consensus...
Q2 Earnings Scorecard and Analyst Reports for Roche, Adobe & McDonald's
Zacks via Yahoo Finance· 2 years agoTuesday, August 9, 2022 The Zacks Research Daily presents the best research output of our analyst...
Private equity’s drive for eye care pushes up costs
Fortune via Yahoo Finance· 2 years agoAs private equity groups are swarming into aging America’s eye care, the consolidation is costing the U.S. health care system and patients more money.